ESMO

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

No benefit for adjuvant durvalumab in completely resected NSCLC

PFS increase but no OS increase for niraparib in advanced ovarian cancer

ESMO 2024